VP, Intelligence Alliances and Product Unification
+27 year(s) experience
Patricia also writes for external partner publications, providing analysis as well as pharma and biotech sector reviews that examine scientific and financial growth. Previously, Patricia led the Citeline CNS, Autoimmune/Inflammation and Ophthalmology therapeutic area teams.
She was also given responsibility for the Medtrack database, which needed extensive editorial revamping and oversight. It has now become an industry-leading product. Before joining Informa in 2004, Patricia worked at Boehringer Ingelheim, first as a research scientist and later in competitive intelligence of the in-licensing group.
By Patricia Reilly 27 Jun 2018
The promises of gene therapy are taking a long time to be fulfilled, in part due to challenges in developing gene vectors capable of safe and efficient delivery of therapeutic genes (transgenes) into patients’ cells. Nonetheless, these challenges are being addressed in innovative ways. A variety of first-generation vectors, both viral and non-viral, have been employed in clinical trials with varying degrees of success, and the experience gained is guiding the design of next-generation vectors.